GLP-1 medicines in the UK: NHS routes, private prescriptions and supply

What is licensed in the UK, and under which name

The same molecule appears under different brand names depending on whether it is licensed for type 2 diabetes or for weight management. Getting the names straight prevents most of the confusion.

• Semaglutide is licensed as Ozempic (injection, type 2 diabetes), Rybelsus (tablet, type 2 diabetes) and Wegovy (injection, weight management).
• Tirzepatide is licensed as Mounjaro, which carries both a type 2 diabetes and a weight-management indication in the UK.
• Liraglutide is licensed as Victoza (diabetes) and Saxenda (weight management), and generic versions have entered the market.
• All of them are prescription-only medicines in the UK. None can be sold over the counter, and none can lawfully be advertised to the public.
• The UK product information for each brand is published on the electronic Medicines Compendium, and that leaflet — not a forum chart — is the document that applies to the pen in your hand.

The NHS route and who is eligible

NICE technology appraisals set the terms on which the NHS funds these medicines, and they are narrower than the license.

• For weight management, NICE guidance ties NHS funding to body mass index thresholds plus weight-related health conditions, and generally to delivery through a specialist weight-management service.
• Those services have limited capacity, so waiting times vary widely between areas and a GP cannot simply issue a prescription outside the appraisal terms.
• For type 2 diabetes, NICE NG28 positions GLP-1 receptor agonists later in the treatment sequence, after metformin and other options, with defined review points.
• NHS prescriptions are dispensed with the usual prescription charge in England, and free of charge in Scotland, Wales and Northern Ireland.

Private prescriptions and what a legitimate one looks like

Most UK weight-management prescriptions today are private. That is entirely lawful — but the standards for how the prescription is issued are not optional.

• A UK-registered prescriber must assess you properly. A photograph and a self-reported weight is not an adequate consultation, and the General Pharmaceutical Council has acted against services that worked that way.
• The pharmacy dispensing it should be registered with the GPhC and identifiable on the public register.
• Prices vary sharply by strength and supplier; escalation to higher strengths usually raises the monthly cost.
• Pens bought from social media sellers or from overseas sites are outside the supply chain. The MHRA has published warnings about counterfeit weight-loss pens, some of which contained insulin and caused hospital admissions.

Supply notices, shortages and what to record

UK supply of these medicines has been interrupted repeatedly, and the practical consequence is unplanned gaps and brand switches.

• The Department of Health and Social Care issues medicine supply notifications when a strength is constrained, sometimes asking prescribers not to start new patients on it.
• If a strength is unavailable, the decision about what to do belongs to the prescriber — changing brand or strength yourself is how dosing errors happen.
• Keep the brand, strength, pen batch number and the date of each injection. If supply forces a switch, that record is what lets a clinician pick up where you left off.
• Record side effects with dates alongside the dose. Nausea in the first week after a step up reads very differently from nausea that starts after three stable months.

References

• electronic Medicines Compendium (emc) — UK product information for GLP-1 medicines
• NICE — technology appraisal guidance on weight-management medicines
• NICE NG28 — type 2 diabetes in adults: management
• MHRA — warnings about falsified weight-loss pens
• General Pharmaceutical Council — registers of pharmacies and pharmacists